Articles tagged with Cancer Medication
Researchers isolated machinery for producing cancer-fighting drug etoposide from endangered Himalayan plant and applied it to a common laboratory plant, producing the chemical. The technique could lead to less expensive and more stable sources of drugs.
A clinical trial using Pembrolizumab plus chemotherapy found the treatment to be safe for patients with advanced small cell and non-small cell lung cancer. The study, led by Dr. Glen Weiss, presented initial results from 12 lung cancer patients enrolled in the 'PembroPlus' clinical trial.
Researchers have found a new strategy to eliminate HIV by reactivating latent infected cells using a class of drugs called Smac mimetics. The approach, which has shown promising results in clinical trials for cancer, may lead to a safe and effective treatment to cure the virus.
A University of Colorado Cancer Center study identified a specific ratio of MET to centromere 7 that defines patients with MET-driven lung cancer susceptible to crizotinib treatment. This threshold has been associated with responses approaching 70 percent in clinical trials.
The study reveals that drugs behave as predicted in the computer-generated model of P-gp, allowing researchers to understand how they bind and inhibit the protein. This breakthrough enables scientists to predict better what will make an inhibitor work, potentially leading to new cancer treatments.
Researchers at UCSF are studying a molecular pathway that underlies many cancers, with the goal of improving diagnosis and treatment. The grant will integrate data from preclinical studies and precision medicine technologies to generate high-resolution molecular information on NF1-associated tumors.
Researchers have found three new drug-like compounds that target a protein responsible for chemotherapy resistance in cancers, offering hope for improved treatment options. The compounds have shown promise in re-sensitizing resistant cancer cells to chemotherapy, improving the odds of survival for prostate cancer patients.
Children's Cancer Institute Australia has been awarded close to $2 million to test new drugs in preclinical models of acute lymphoblastic leukaemia (ALL) under the Pediatric Preclinical Testing Consortium (PPTC). The PPTC will facilitate the acceleration of effective drugs into clinical trials.
Researchers at UC San Diego School of Medicine identified a new pathway that causes resistance to treatments, and developed a therapeutic drug that targets this pathway. The drug, KG5, inhibits the pathway and increases survival rates among patients with aggressive cancers.
Researchers discover that altering protein recycling complexes in human cells enables cancer cells to resist treatment with proteasome inhibitors, a class of drugs used to kill cancer cells. The discovery highlights the potential for targeting this resistant state to develop new cancer treatments.
Researchers at Baylor College of Medicine have discovered a new way to kill cancers driven by the MYC gene, which is responsible for aggressive behavior in many types of malignancies. By inhibiting the spliceosome, a complex machine within cancer cells, scientists can target and destroy tumor cells without harming normal tissues.
A new study found that using a patient's entire genome helped suggest personalized treatment options for nearly half of children with cancer. The approach led to specific treatment changes in a quarter of these patients and showed promise in treating difficult-to-treat cancers.
The new Northwestern University Center for Cancer Nanotechnology Excellence will use nucleic-acid-based nanoconstructs called Spherical Nucleic Acids (SNAs) to discover new aspects of cancer biology and create effective cancer treatment options. SNAs are nontoxic to humans, offering a versatile tool in medicine.
Researchers at Ohio State University Comprehensive Cancer Center have designed an online database called CanDL to help molecular pathologists identify key cancer gene mutations. The freely accessible database includes information on 60 genes, 334 distinct variants and 169 unique matching literature references across multiple cancers.
Researchers found a core group of genes related to both viral defense and susceptibility to demethylating drug 5-azacytidine. The study suggests that triggering this pathway may improve the effectiveness of immunotherapy drugs in patients with certain types of cancer.
Researchers create economic model to assess life expectancy, management of adverse effects, and quality of life for new oncology drugs like necitumumab. The study finds that the value-based price for necitumumab ranges between $563 and $1,309 per three-week cycle.
A research team has discovered a mechanism to mimic a viral infection in colon cancer stem cells, which could potentially trigger an immune response to fight the disease. Decitabine, a chemotherapy drug, is identified as a potential target to induce viral mimicry and activate an anti-viral response.
A recent study suggests that nitroglycerin could be repurposed as an anti-cancer treatment by improving tumor oxygenation and delivering anticancer drugs. The medication, traditionally used for chest pain, has excellent potential for patient benefit without significant side effects.
Researchers are exploring clinical trials on dogs with naturally occurring cancer to develop new treatments for humans. By studying the genetic basis of canine tumors, scientists hope to gain valuable insights into human cancer treatment.
A recent study published in the Journal of Geriatric Oncology found that 26% of senior oncology patients use complementary or alternative medicines, which can interact with cancer treatments. The study highlights the need for comprehensive screening and documentation of CAM use in older cancer patients.
University of Houston researchers identify liver X receptors as a promising target for developing new pancreatic cancer treatments. The study, led by Chin-Yo Lin, shows that targeting these receptors can slow the growth of tumors and is expected to lead to the development of new drugs.
A new analysis found that patients taking certain heart medications to manage stress may have a longer survival time than those not taking these drugs. Nonselective beta blockers showed the most significant benefit in extending median survival time, particularly among patients with hypertension.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Researchers from MSK Cancer Center announce results from the first published basket study, a clinical trial design that explores drug responses based on specific tumor mutations. The study found preliminary clinical efficacy of vemurafenib in multiple non-melanoma BRAFV600-mutated cancers.
Researchers tested the novel next-generation small molecule drug SGI-110 in MDS and AML patients, revealing it is well-tolerated and biologically active. The study found potent dose-related DNA demethylation associated with clinical response, showing promise for treating leukemia patients.
The ECOG-ACRIN Cancer Research Group has opened the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial. The trial seeks to enroll approximately 3,000 adults with solid tumors or lymphoma who have returned or worsened after standard therapy.
Researchers from Boston University School of Medicine find no evidence of association between Post Traumatic Stress Disorder (PTSD) and cancer incidence. The large population sample analyzed various cancer diagnoses among people with PTSD compared to the general population, showing no strong associations even among select groups.
Organ transplant recipients are more susceptible to developing regional stage melanoma due to immunosuppressive medications. The study found that transplant patients were four times more likely to be diagnosed with regional stage melanoma and three times more likely to die from the disease.
Researchers discovered that treating tumors with chemotherapy can trigger a response in the immune system, leading to tumor growth. By combining chemotherapy with an immune-blocking drug, they found that this response could be slowed, potentially preventing tumor regrowth.
The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead centers participating in the National Cancer Institute's MATCH Trial. The trial seeks to determine whether targeted therapies for people with tumors having specific gene mutations will be effective.
A new cancer drug candidate, MCB-613, stimulates proteins crucial for tumor growth, causing cell stress and death. It efficiently kills human cancer cells while sparing normal cells, showing promise as a treatment for a range of cancers.
Researchers found that miR-7 directly targets and suppresses the activity of growth factor receptor IGF1R, as well as the pro-oncogenic NF-κB pathway. Increasing miR-7 levels reduced tumor growth in mice and correlated with improved patient survival.
A new algorithm developed by InSilico Medicine has the potential to improve the effectiveness of targeted therapy for cancer patients. The algorithm predicts whether a specific drug will work for an individual patient based on activation of intracellular regulatory pathways.
A LA BioMed researcher is launching a study of medication adherence among dialysis patients, aiming to improve patient health outcomes. The researcher will examine the factors contributing to non-adherence and its impact on cardiovascular disease risk.
Worcester Polytechnic Institute researcher Amity Manning is awarded $747,000 from the National Institutes of Health to explore molecular mechanisms driving genetic instability in cancer cells. The goal is to turn the genetic tables against cancer by understanding how specific molecules affect DNA packaging and organization.
Patients with metastatic prostate cancer who received a two-drug combination of chemotherapy and hormone blocker lived longer than those on hormone-blocker alone, surviving for 57.6 months versus 44 months. The treatment also delayed disease progression by six months.
Researchers at Sanford Burnham Prebys Medical Discovery Institute solved the structure of hypoxia-inducible factors (HIFs), important regulators of tumor response to low oxygen. The findings identify potential targets for new cancer drugs, which could inhibit HIF functions and reduce tumor growth.
Researchers at Duke University have successfully packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness in mice. The new approach delivers the drug directly to tumors while reducing side effects and improving targeting, showing transformative results for patients.
New research published in Science Translational Medicine found that smaller doses of resveratrol are more effective in preventing bowel cancer in mice than high doses. The study showed a 50% reduction in tumour size with lower doses compared to a 25% reduction with higher doses.
A new tool called the Kinase Addiction Ranker (KAR) improves the ability to match drugs to disease by predicting what genetics are truly driving a patient's cancer. The tool clarifies the best drug or combination of drugs that targets specific genetic abnormalities, leading to more effective treatment options.
A study by MIT economists found that pharmaceutical firms tend to invest more in drugs for earlier-stage cancers, resulting in a lack of investment in late-stage cancer treatments. This has resulted in a loss of 890,000 life-years among people diagnosed with cancer in 2003.
Researchers have established the safety and dosing of a new drug for treating blood cancers, targeting dormant cancer stem cells. The drug coaxes these cells to differentiate and exit the bone marrow, where they can be destroyed by chemotherapy agents.
Leading cancer experts recommend several measures to reduce high cancer drug prices, including a post-approval price review mechanism and Medicare negotiations. The recommendations aim to improve patient care and alleviate the financial burden on those affected by high cancer drug costs.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a new way to improve liver cancer treatment by blocking the activity of the lymphotoxin-beta receptor. The approach, which combines drugs currently in clinical trials with those targeting oncogene signals, may lead to improved patient outcomes.
Mayo researchers found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment in anaplastic thyroid cancer. The study identified vorinostat and belinostat as effective agents, which can increase activity of RhoB, a tumor suppressor and stimulate cell death.
Researchers have developed a new drug, CCT245737, that blocks cancer's escape route from chemotherapy, boosting its effectiveness in treating lung and pancreatic cancers. The drug, a CHK1 inhibitor, demonstrates significant anti-cancer activity when combined with chemotherapy in mice.
A major study of over 30,000 women shows that aromatase inhibitors substantially reduce the risk of death from ER-positive breast cancer. Taking aromatase inhibitors for five years reduces the risk of death by 40% compared to tamoxifen.
The Institute for Clinical and Economic Review (ICER) has launched a new program to provide independent analysis on pricing linked to patient benefit for new FDA-approved drugs. The program will produce public reports near the time of FDA approval, providing a transparent basis for price negotiations and coverage decisions.
A new website, the Chemical Probes Portal, aims to guide researchers in selecting better-quality chemical probes, reducing errors and wasting time and money. The platform crowdsources knowledge from leading researchers, providing up-to-date comparative information to help users choose the best probe for their needs.
A national clinical trial involving two effective drug combinations will be compared in a new study. The trial, led by Dr. Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, aims to determine the best sequencing of treatment regimens for patients with melanoma.
Patients with advanced disease experienced significant clinical response after receiving genetically engineered T-cells. The therapy was generally well-tolerated and showed long-term ability to fight tumors.
Researchers at the University of Copenhagen have developed a novel technique to improve glycoprotein-based pharmaceuticals, resulting in better therapeutic effects, longer durations, and faster production. The technology holds considerable potential for improving existing pharmaceuticals and has been published in Nature Biotechnology.
A third of insured breast cancer survivors in Appalachia are not taking critical follow-up treatment, despite having insurance that would cover it. Researchers found that geographical barriers, slower adoption of new technologies, and lack of proper counseling on medication side effects contribute to the issue.
Researchers at Stanford University School of Medicine have developed a database that integrates gene expression patterns of 39 types of cancer with data on patient survival rates. The PRECOG database identifies key pathways and genes associated with poor or good survival outcomes, including FOXM1 and KLRB1.
Researchers found a metabolic imbalance that is oncogenic in diffuse large B-cell lymphomas, characterized by a deficiency of alpha-ketoglutarate. This imbalance disrupts dioxygenase function, leading to various disturbances. The study suggests that metabolic regulation plays a critical role in cancer biology.
Researchers at Oregon State University have developed a system to increase bioavailability of resveratrol and quercetin, potentially allowing extensive use of Adriamycin while reducing cardiac toxicity. The co-administration of these polyphenols enhances the efficacy of cancer drugs by sensitizing cancer cells.
Researchers at University of Hawai'i Cancer Center discover two compounds that effectively stop the growth of brain cancer cells and breast tumors. These targeted treatments are less toxic and could improve quality of life for patients with no effective treatment options besides surgery.
Scientists designed nanoparticles that release chemotherapy drugs paclitaxel in the presence of matrix metalloproteinases (MMPs), which enable cancer metastasis. The system effectively delivers high doses of the drug, halting tumor growth and reducing toxicity.
Researchers developed a new compound that stops B-cell acute lymphoblastic leukemia by locking a disease-related protein in an inactive state. The compound showed promise in animal studies, with improved survival rates and reduced side effects when combined with steroids.